<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35311469</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1525-6049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Renal failure</Title>
          <ISOAbbreviation>Ren Fail</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Relaxin inhibits renal fibrosis and the epithelial-to-mesenchymal transition via the Wnt/β-catenin signaling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>513</StartPage>
          <EndPage>524</EndPage>
          <MedlinePgn>513-524</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2022.2044351</ELocationID>
        <Abstract>
          <AbstractText>Renal fibrosis is a common characteristic and the final pathological mechanism of chronic kidney disease (CKD). Although CKD remains incurable, inhibition of renal fibrosis is beneficial to inhibit the CKD process. Relaxin alleviates renal fibrosis in some experimental models, but its mechanism remains unclear. In the following, we studied the regulatory effect of relaxin on epithelial-mesenchymal transition (EMT) after unilateral ureteral obstruction (UUO). Our results demonstrate that relaxin could downregulate Wnt/β-catenin signaling and decrease EMT, thus protecting against loss of transporters in tubular epithelial cells (TECs) and abrogate renal interstitial fibrosis following UUO. We confirmed that relaxin can downregulate Wnt/β-catenin signaling and decrease EMT in NRK52E, thus abrogating G2 cell cycle arrest <i>in vitro</i> experiments. Therefore, a novel mechanism by which relaxin is antifibrotic is that relaxin regulates the EMT program of TECs <i>via</i> Wnt/β-catenin signaling pathway. The inhibition of EMT contributes to protecting the functional capabilities of TECs and promoting the regeneration of TECs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Feiteng</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lei</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chaoliang</LastName>
            <ForeName>Xu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zijie</LastName>
            <ForeName>Xu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yi</LastName>
            <ForeName>Shao</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Minglei</LastName>
            <ForeName>Sha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Geriatric, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ren Fail</MedlineTA>
        <NlmUniqueID>8701128</NlmUniqueID>
        <ISSNLinking>0886-022X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C492607">Rln1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-69-1</RegistryNumber>
          <NameOfSubstance UI="D012065">Relaxin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012065" MajorTopicYN="N">Relaxin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="Y">Wnt Signaling Pathway</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Renal fibrosis</Keyword>
        <Keyword MajorTopicYN="N">chronic kidney disease</Keyword>
        <Keyword MajorTopicYN="N">epithelial-to-mesenchymal</Keyword>
        <Keyword MajorTopicYN="N">unilateral ureteral obstruction</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>12</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35311469</ArticleId>
        <ArticleId IdType="pmc">PMC8942541</ArticleId>
        <ArticleId IdType="doi">10.1080/0886022X.2022.2044351</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bikbov B, Purcell CA, Levey AS, et al. . 
Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709–733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7049905</ArticleId>
            <ArticleId IdType="pubmed">32061315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drawz P, Rahman M.. 
Chronic kidney disease. Ann Intern Med. 2015;162(11):ITC1–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26030647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y.
Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7(12):684–696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4520424</ArticleId>
            <ArticleId IdType="pubmed">22009250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphreys BD.
Mechanisms of renal fibrosis. Annu Rev Physiol. 2018;80:309–326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29068765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwano M, Plieth D, Danoff TM, et al. . 
Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 2002;110(3):341–350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151091</ArticleId>
            <ArticleId IdType="pubmed">12163453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamouille S, Xu J, Derynck R.. 
Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4240281</ArticleId>
            <ArticleId IdType="pubmed">24556840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LeBleu VS, Taduri G, O'Connell J, et al. . 
Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013;19(8):1047–1053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4067127</ArticleId>
            <ArticleId IdType="pubmed">23817022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jourde-Chiche N, Fakhouri F, Dou L, et al. . 
Endothelium structure and function in kidney health and disease. Nat Rev Nephrol. 2019;15(2):87–108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30607032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y.
Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol. 2004;15(1):1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14694152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lovisa S, LeBleu VS, Tampe B, et al. . 
Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med. 2015;21(9):998–1009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4587560</ArticleId>
            <ArticleId IdType="pubmed">26236991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, Besschetnova TY, Brooks CR, et al. . 
Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med. 2010;16(5):535–543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3928013</ArticleId>
            <ArticleId IdType="pubmed">20436483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samuel CS, Hewitson TD.. 
Relaxin and the progression of kidney disease. Curr Opin Nephrol Hypertens. 2009;18(1):9–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19077683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samuel CS, Hewitson TD, Unemori EN, et al. . 
Drugs of the future: the hormone relaxin. Cell Mol Life Sci. 2007;64(12):1539–1557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17458501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang X, Thorngren D, Chen Q, et al. . 
Protective role of relaxin in a mouse model of aristolochic acid nephropathy. Biomed Pharmacother. 2019;115:108917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31060002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garber SL, Mirochnik Y, Brecklin CS, et al. . 
Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int. 2001;59(3):876–882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11231342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teerlink JR, Cotter G, Davison BA, et al. . 
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23141816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mookerjee I, Hewitson TD, Halls ML, et al. . 
Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. Faseb J. 2009;23(4):1219–1229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19073841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heeg MHJ, Koziolek MJ, Vasko R, et al. . 
The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int. 2005;68(1):96–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15954899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramos-Vara JA.
Principles and methods of immunohistochemistry. Methods Mol Biol. 2011;691:83–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20972748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee SY, Jeon HM, Ju MK, et al. . 
Wnt/snail signaling regulates cytochrome C oxidase and glucose metabolism. Cancer Res. 2012;72(14):3607–3617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22637725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stemmer V, de Craene B, Berx G, et al. . 
Snail promotes Wnt target gene expression and interacts with beta-catenin. Oncogene. 2008;27(37):5075–5080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18469861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajasekaran SA, Huynh TP, Wolle DG, et al. . 
Na,K-ATPase subunits as markers for epithelial-mesenchymal transition in cancer and fibrosis. Mol Cancer Ther. 2010;9(6):1515–1524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2884047</ArticleId>
            <ArticleId IdType="pubmed">20501797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Meng Q, Wang C, et al. . 
Changes in expression of renal Oat1, Oat3 and Mrp2 in cisplatin-induced acute renal failure after treatment of JBP485 in rats. Toxicol Appl Pharmacol. 2012;264(3):423–430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22992436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chow BSM, Chew EGY, Zhao C, et al. . 
Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. PLoS One. 2012;7(8):e42714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3425563</ArticleId>
            <ArticleId IdType="pubmed">22936987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He W, Dai C, Li Y, et al. . 
Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol. 2009;20(4):765–776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2663839</ArticleId>
            <ArticleId IdType="pubmed">19297557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson PJ, von Toerne C, Gröne H-J.. 
Wnt-signaling pathways in progressive renal fibrosis. Expert Opin Ther Targets. 2011;15(9):1073–1083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21623684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Surendran K, Schiavi S, Hruska KA.. 
Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol. 2005;16(8):2373–2384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15944336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He W, Kang YS, Dai C, et al. . 
Blockade of wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol. 2011;22(1):90–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3014038</ArticleId>
            <ArticleId IdType="pubmed">21030600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao S, He W, Li Y, et al. . 
Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol. 2011;22(9):1642–1653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3171936</ArticleId>
            <ArticleId IdType="pubmed">21816937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He W, Tan R, Dai C, et al. . 
Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of wnt/beta-catenin signaling. J Biol Chem. 2010;285(32):24665–24675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2915703</ArticleId>
            <ArticleId IdType="pubmed">20519507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strutz F, Okada H, Lo CW, et al. . 
Identification and characterization of a fibroblast marker: FSP1. J Cell Biol. 1995;130(2):393–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2199940</ArticleId>
            <ArticleId IdType="pubmed">7615639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeisberg EM, Potenta SE, Sugimoto H, et al. . 
Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008;19(12):2282–2287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2588112</ArticleId>
            <ArticleId IdType="pubmed">18987304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burns WC, Twigg SM, Forbes JM, et al. . 
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol. 2006;17(9):2484–2494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16914537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Djamali A, Reese S, Yracheta J, et al. . 
Epithelial-to-mesenchymal transition and oxidative stress in chronic allograft nephropathy. Am J Transplant. 2005;5(3):500–509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15707404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossini M, Cheunsuchon B, Donnert E, et al. . 
Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease. Kidney Int. 2005;68(6):2621–2628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16316338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hills CE, Squires PE.. 
The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev. 2011;22(3):131–139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21757394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grande MT, Sánchez-Laorden B, López-Blau C, et al. . 
Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med. 2015;21(9):989–997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26236989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphreys BD, Valerius MT, Kobayashi A, et al. . 
Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell. 2008;2(3):284–291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18371453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonventre JV.
Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol. 2003;14(Suppl 1):S55–S61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12761240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang HM, Ahn SH, Choi P, et al. . 
Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21(1):37–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4444078</ArticleId>
            <ArticleId IdType="pubmed">25419705</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
